Search Result

Search Result

Results for "

Porphyria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (3) Endogenous Metabolite (4) Herbicide (4) Isotope-Labeled Compounds (1) LYTACs (1) Reference Standards (2) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Metabolic Disease (9) Neurological Disease (3)
Oligonucleotides:	siRNA drugs (3) siRNAs (3)

12

Inhibitors & Agonists

3

Natural
Products

1

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Hematin	Cytochrome P450	Metabolic Disease Cancer
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .

Givosiran sodium 1 Publications Verification ALN-AS1 sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP) .

Givosiran 1 Publications Verification ALN-AS1	Small Interfering RNA (siRNA)	Metabolic Disease
Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP) .

Succinyl-Coenzyme A sodium 2 Publications Verification Succinyl-CoA sodium	Endogenous Metabolite	Neurological Disease Metabolic Disease
Succinyl-Coenzyme A (Succinyl-CoA) sodium is an intermediate of the citric acid cycle. Succinyl-Coenzyme A sodium can be converted to succinic acid and can also combines with glycine to form δ-ALA to synthesize porphyrins (heme). Succinyl-Coenzyme A sodium can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B₁₂ deficiency (resulting in a deficiency in Succinyl-Coenzyme A synthesis) .

Coproporphyrin I-15N4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Coproporphyrin I- ¹⁵N₄ is a ¹⁵N-labeled Coproporphyrin I (HY-113318). Coproporphyrin I is an endogenous metabolite present in urine and blood that can be used for the research of liver disease and porphyria .

Oxadiazon	Herbicide Cytochrome P450	Neurological Disease Metabolic Disease
Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .

Oxadiazon (Standard)	Herbicide Reference Standards Cytochrome P450	Neurological Disease Metabolic Disease
Oxadiazon (Standard) is the analytical standard of Oxadiazon (HY-B1880). This product is intended for research and analytical applications. Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .

GalNac-siRNA negative control (21nt)	LYTACs	Cardiovascular Disease
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

Succinyl CoA Succinyl-coenzyme A; S-(Hydrogen succinyl)coenzyme A	Endogenous Metabolite	Metabolic Disease
Succinyl CoA is an intermediate of the citric acid cycle. Succinyl CoA can be converted to succinic acid and can also combines with glycine to form δ-amino levulinic acid (ALA) to synthesize porphyrins (heme). Succinyl CoA can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B12 deficiency (resulting in a deficiency in Succinyl CoA synthesis) .

Coproporphyrin I	Endogenous Metabolite	Metabolic Disease
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

Butafenacil (Standard) WC-9717 (Standard); CGA-276854 (Standard)	Herbicide Reference Standards	Others
Butafenacil (Standard) is the analytical standard of Butafenacil. This product is intended for research and analytical applications. Butafenacil (WC-9717; CGA-276854) is an herbicide that inhibits protoporphyrinogen oxidase .

Butafenacil WC-9717; CGA-276854	Herbicide	Others
Butafenacil (WC-9717; CGA-276854) is an herbicide that inhibits protoporphyrinogen oxidase .

Cat. No.	Product Name	Category	Target	Chemical Structure

Succinyl-Coenzyme A sodium 2 Publications Verification Succinyl-CoA sodium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Succinyl-Coenzyme A (Succinyl-CoA) sodium is an intermediate of the citric acid cycle. Succinyl-Coenzyme A sodium can be converted to succinic acid and can also combines with glycine to form δ-ALA to synthesize porphyrins (heme). Succinyl-Coenzyme A sodium can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B₁₂ deficiency (resulting in a deficiency in Succinyl-Coenzyme A synthesis) .

Succinyl CoA Succinyl-coenzyme A; S-(Hydrogen succinyl)coenzyme A	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Endogenous Metabolite
Succinyl CoA is an intermediate of the citric acid cycle. Succinyl CoA can be converted to succinic acid and can also combines with glycine to form δ-amino levulinic acid (ALA) to synthesize porphyrins (heme). Succinyl CoA can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B12 deficiency (resulting in a deficiency in Succinyl CoA synthesis) .

Coproporphyrin I	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

Cat. No.	Product Name	Chemical Structure

Coproporphyrin I-15N4
Coproporphyrin I- ¹⁵N₄ is a ¹⁵N-labeled Coproporphyrin I (HY-113318). Coproporphyrin I is an endogenous metabolite present in urine and blood that can be used for the research of liver disease and porphyria .

Cat. No.	Product Name		Classification

Givosiran sodium 1 Publications Verification ALN-AS1 sodium		siRNAs siRNA drugs
Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP) .

Givosiran 1 Publications Verification ALN-AS1		siRNAs siRNA drugs
Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP) .

GalNac-siRNA negative control (21nt)		siRNAs siRNA drugs
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us